Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of theaflavin as synergist of antifungal medicine

An antifungal drug, theaflavin technology, applied in the field of medicine, can solve the problems of no fungal disease, no antifungal effect, etc., and achieve the effects of improving the antifungal effect, saving medical expenses, and reducing the dosage of drugs

Inactive Publication Date: 2010-09-01
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Theaflavins also have antibacterial effects, but have no antifungal effects, and there are no reports of using them as a synergist in combination with antifungal drugs to treat fungal diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of theaflavin as synergist of antifungal medicine
  • Application of theaflavin as synergist of antifungal medicine
  • Application of theaflavin as synergist of antifungal medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0006] Example 1: Effects of theaflavin and fluconazole in combination on different clinical fungal strains

[0007] Materials and methods

[0008] 1. Test drug:

[0009] Theaflavins: Wuhan Yuancheng Technology Development Co., Ltd.

[0010] Fluconazole injection: Pfizer Pharmaceutical Co., Ltd., batch number 9167802.

[0011] Dimethyl sulfoxide: Shanghai Shiyi Biotechnology Co., Ltd.

[0012] Theaflavin is made into solution with dimethyl sulfoxide, the concentration is 6.4mg / ml. All reagents were stored at -20°C. Before the experiment, the drug was taken out and placed in a 35°C incubator to melt, mixed well, and pharmacodynamic tests were carried out respectively.

[0013] 2. Strains:

[0014] Clinical strains: drug-resistant Candida albicans, including five strains 103, 17, 18, 38, and 0710448, and Candida tropicalis, including five strains 409, 936, 422, 0710453, and 0710087, all provided by the Mycology Department of Shanghai Changhai Hospital. Clinical samples fr...

Embodiment 2

[0043] Example 2: Combination of theaflavins and other azole antifungal drugs

[0044] Materials and methods

[0045] 1. Drugs

[0046] Itraconazole: Provided by the School of Pharmacy, Second Military Medical University

[0047] Ketoconazole: Provided by the School of Pharmacy, Second Military Medical University

[0048] Miconazole: Provided by the School of Pharmacy, Second Military Medical University

[0049] Itraconazole, ketoconazole and miconazole dimethyl sulfoxide were formulated to 6.4 mg / ml, theaflavins were formulated to 6.4 mg / ml with dimethyl sulfoxide, and each reagent was stored at -20°C. Before the experiment, the drug was taken out and placed in a 35°C incubator to melt, mixed well, and pharmacodynamic tests were carried out respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to new application of theaflavin as a synergist of antifungal drugs. Through in vitro experiments, when used together with fluconazole, itraconazole, miconazole, ketoconazole and other antifungal drugs, theaflavin can increase therapeutic effect on slight surface and deep fungus infection to some extent and can restore the effect of the antifungal drugs on drug-resisting fungi. Therefore, the theaflavin can be used as the synergist of the antifungal drugs. The invention provides new application for the theaflavin; when used as the synergist of the antifungal drugs, the theaflavin not only can increase the antifungal effect of the drugs, but also can restore the effect of the antifungal drugs on the drug-resisting fungi in the condition that clinic fungal drug resistance is more and more common and drug resistance degree is more and more serious. The application dosage of the antifungal drugs can be reduced, so that medical expenses can be saved for patients, and the toxic and side effects of the drugs are reduced.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to a new application of theaflavin as a synergist for antifungal drugs. Background technique [0002] Theaflavin is one of the tea polyphenols. Studies have shown that theaflavin has the effect of regulating blood lipids, preventing cardiovascular diseases, and has a unique function of lowering blood lipids. Theaflavins are not only an effective free radical scavenger and anti Oxidant, and has various physiological functions such as anti-cancer, anti-mutation, improvement and treatment of cardiovascular and cerebrovascular diseases, and treatment of diabetes. Its role in food, medicine and health care is becoming more and more prominent. Theaflavins also have antibacterial effects, but have no antifungal effects, and there are no reports of their combined use as a synergist and antifungal drugs to treat fungal diseases. Contents of the invention [0003] The invention provides a n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/353A61K31/4196A61K31/496A61K31/4174A61P31/10
Inventor 刘银丽刘伟曹永兵姜远英
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com